Values of serum sFlt-1, PLGF levels, and sFlt-1/PLGF ratio in diagnosis and prognosis evaluation of preeclamptic patients. (2nd October 2020)

• Record Type: Journal Article
• Authors: Zhu, Xiaohe; Chen, Limin; Li, Ran
• Is Part Of: Clinical and experimental hypertension. Volume 42:Number 7(2020)
• Page Start: 601
• Page End: 607
• Publication Date: 2020-10-02
• Subjects: sFlt-1 -- PLGF -- sFlt-1/PLGF -- fetal growth restriction -- preeclampsia; Hypertension -- Chemotherapy -- Periodicals; Hypotensive agents -- Periodicals; 616.132
• DOI: 10.1080/10641963.2020.1756313
• Languages: English
• ISSNs: 1064-1963

Abstract

ABSTRACT: Purpose: To explore the values of serum sFlt-1, PLGF levels and sFlt-1/PLGF ratio in the diagnosis and prognosis evaluation of preeclamptic patients. Methods: From March 2017 to October 2018, 60 cases of early onset preeclampsia (E-PE), 116 cases of late onset preeclampsia (L-PE) and 50 cases of gestational hypertension (GH) were selected. Fifty women who had vaginal bleeding or abdominal distention before 34 gestational weeks were selected as an early control group, and 50 pregnant women awaiting delivery were selected as a late control group. Serum sFlt-1 and PLGF levels were measured, and changes of sFlt-1/PLGF ratio were analyzed. Their correlations with neonatal birth weight were analyzed, and ROC curves were plotted for E-PE diagnosis. Results: The sFlt-1/PLGF ratio of patients with E-PE was significantly higher than those of other groups, and negatively correlated with neonatal birth weight. When the ratio was used as a diagnostic index, AUC was 0.975. The ratio of patients with severe L-PE exceeded that of cases with mild L-PE. In all preeclamptic patients, the ratio was elevated with increasing maternal and neonatal complications. Conclusion: sFlt-1/PLGF ratio is valuable for assessing the severity of preeclampsia and diagnosing E-PE, and can be used to predict neonatal birth weight.